Victory Capital Management
CRNX

Victory Capital Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Victory Capital Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.48M Sell
93,112
-6,252
-6% -$232K ﹤0.01% 1475
2026
Q1 		$3.61M Sell
99,364
-39,321
-28% -$1.76M ﹤0.01% 1433
2025
Q4 		$6.46M Sell
138,685
-94,701
-41% -$4.22M ﹤0.01% 1218
2025
Q3 		$9.72M Sell
233,386
-28,145
-11% -$900K 0.01% 1117
2025
Q2 		$7.52M Buy
261,531
+10,200
+4% +$315K ﹤0.01% 1193
2025
Q1 		$8.43M Sell
251,331
-30,120
-11% -$1.12M 0.01% 1115
2024
Q4 		$14.4M Sell
281,451
-61,893
-18% -$3.46M 0.01% 955
2024
Q3 		$17.5M Buy
343,344
+116,657
+51% +$6.02M 0.02% 895
2024
Q2 		$10.2M Sell
226,687
-30,458
-12% -$1.41M 0.01% 1073
2024
Q1 		$12M Buy
257,145
+73,038
+40% +$2.86M 0.01% 1006
2023
Q4 		$6.55M Buy
184,107
+139,117
+309% +$4.27M 0.01% 1187
2023
Q3 		$1.34M Buy
+44,990
New +$927K ﹤0.01% 1519
2023
Q1 		– Sell
-66,428
Closed -$1.22M – 2611
2022
Q4 		$1.22M Sell
66,428
-32,640
-33% -$575K ﹤0.01% 1632
2022
Q3 		$1.95M Sell
99,068
-11,210
-10% -$229K ﹤0.01% 1462
2022
Q2 		$2.06M Hold
110,278
– – ﹤0.01% 1447
2022
Q1 		$2.42M Sell
110,278
-4,490
-4% -$90.9K ﹤0.01% 1439
2021
Q4 		$3.26M Sell
114,768
-80,670
-41% -$1.99M ﹤0.01% 1417
2021
Q3 		$4.11M Buy
195,438
+115,820
+145% +$2.42M ﹤0.01% 1381
2021
Q2 		$1.5M Sell
79,618
-3,540
-4% -$62.2K ﹤0.01% 1720
2021
Q1 		$1.27M Buy
83,158
+30,720
+59% +$476K ﹤0.01% 1802
2020
Q4 		$740K Sell
52,438
-9,240
-15% -$129K ﹤0.01% 1906
2020
Q3 		$966K Sell
61,678
-2,080
-3% -$31.8K ﹤0.01% 1718
2020
Q2 		$1.12M Sell
63,758
-120,966
-65% -$2.06M ﹤0.01% 1680
2020
Q1 		$2.71M Sell
184,724
-10,514
-5% -$215K ﹤0.01% 1246
2019
Q4 		$4.9M Sell
195,238
-19,130
-9% -$364K 0.01% 1193
2019
Q3 		$3.22M Buy
214,368
+144,698
+208% +$2.81M ﹤0.01% 1301
2019
Q2 		$1.74M Buy
69,670
+16,300
+31% +$404K ﹤0.01% 1176
2019
Q1 		$1.22M Sell
53,370
-590
-1% -$14.5K ﹤0.01% 1210
2018
Q4 		$1.62M Sell
53,960
-40,850
-43% -$1.15M ﹤0.01% 1093
2018
Q3 		$2.72M Buy
+94,810
New +$2.81M 0.01% 1036

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Victory Capital Management's CRNX Position: Q2 2026 in Review

Victory Capital Management reduced its Crinetics Pharmaceuticals (CRNX) stake by 6.3% in Q2 2026, selling an estimated $232K and leaving 93,112 shares worth $3.48M. The position accounts for ﹤0.01% of the portfolio, ranked #1475.

Victory Capital Management first reported a position in CRNX in Q3 2018 and has held it in 30 quarters since. The position peaked at $17.5M in Q3 2024. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Victory Capital Management held 93,112 shares of Crinetics Pharmaceuticals worth $3.48M as of Q2 2026.
  • Victory Capital Management sold 6,252 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $232K.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Victory Capital Management's portfolio in Q2 2026, its #1475 holding.
  • Victory Capital Management first reported a position in Crinetics Pharmaceuticals in Q3 2018 and has held it in 30 quarters since.
  • Victory Capital Management's Crinetics Pharmaceuticals position peaked at $17.5M in Q3 2024.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.